Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Learn more about:
Related Clinical Trial
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma